Autopsy report · NCT03457818

Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab

“Due to enrollment difficulties compounded by the COVID pandemic.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 10 months before it started.
• Ran for about 1 year 7 months before it stopped.
• 8 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Mishaela Rubin

Sponsor type

University, hospital or other

Conditions

Diabetes Mellitus, Type 2; Osteoporosis

Interventions

Denosumab 60 mg/ml [Prolia]; Placebo

Participants

8

Sites

1

Countries

United States

Trials that died the same way

• Quality of Life Changes on Lower Extremity Lymphedema Patients Using an Advanced Pneumatic Compression Device (PCD)
  “Due to slow enrollment during COVID” (81% match in meaning)
• Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases
  “Enrollment was affected due to the COVID-19 pandemic” (81% match in meaning)
• Oxidative Stress and Circulating Nuclear DNA (cfDNA) in Acute Kidney Injury and Continuous Renal Replacement Therapies.
  “Enrollment slower than anticipated and interrupted by COVID-19 pandemic” (77% match in meaning)
• The Safety of Transdermal Nicotine Immediately Following an Acute Coronary Syndrome
  “Difficulties with enrollment.” (75% match in meaning)
• Social Engagement Strategies to Improve Medication Adherence
  “Inability to complete enrollment caused by COVID-19 and underpowered to conduct analysis” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.